DMAC earnings date and last-quarter result: last quarter in line, P/E -9.77. Updated 2026-07-23.
DiaMedica Therapeutics (DMAC) Research Hub
DiaMedica Therapeutics (DMAC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 8.74 USD (+0.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.77, market cap 0.38B. This hub links to the full technical, earnings and options research available for DMAC.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.74 USD (+0.23%) |
| 52-week range | 5.56 USD – 8.95 USD |
| Trend regime | Range |
| 14-day RSI | 59.3 (Bullish) |
| Trailing P/E | -9.77 |
| Market cap | 0.38B |
| Dividend yield | 0.00% |
Available research for DMAC
Covered Call on DMAC: how it works, illustrative setup around the real 8.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DMAC: how it works, illustrative setup around the real 8.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DMAC: how it works, illustrative setup around the real 8.74 USD price, max profit/loss, breakeven and when to use it. Educational.
DMAC technical analysis: range, last 8.74 USD, RSI 59.3, 52w range 5.56 USD–8.95 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DMAC in?
DiaMedica Therapeutics (DMAC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DMAC in an uptrend or downtrend?
As of 2026-10-26, DMAC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DMAC's trailing P/E ratio?
DMAC's trailing P/E is -9.77, with a market cap of 0.38B. See the earnings research page for full valuation detail.